Hospital Del Mar

Running trials

• Not yet recruiting

  A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC

  2026-526300-67-00· Phase 3· Summit Therapeutics Inc.· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Recruiting

  Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  2025-523288-39-00· Phase 2· Mediar Therapeutics Inc.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

  NCT07814417· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source

• Recruiting

  A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

  NCT07465757· Phase 2· Puma Biotechnology, Inc.· Source

• Not yet recruiting

  Extracorporeal Carbon Dioxide Removal Plus Noninvasive Ventilation in Patients With COPD Not Eligible for Intubation

  NCT07785375· Hospital del Mar Research Institute (IMIM)· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

  NCT07686263· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis

  NCT07310862· Clarity Health Technologies, Inc· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

  NCT07864207· Phase 1/2· IDP Discovery Pharma S.L.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.

  2025-522076-85-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)

  2025-521902-17-00· Phase 1/2· Idp Discovery Pharma S.L.· Source

• Recruiting

  Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  NCT07489066· Phase 2· Pfizer· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial

  2025-524078-40-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· Phase 3· Ferrer Internacional S.A.· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.

  NCT07593820· Phase 1· Vall d'Hebron Institute of Oncology· Source

• Recruiting

  Phase 2 Study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea.

  2025-523864-19-00· Phase 2· Oryzon Genomics S.A.· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Liquidia Technologies, Inc.· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Recruiting

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria

  2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source

• Recruiting

  Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

  NCT07394153· Phase 2· Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Treatment for Ph-negative ALL for Adults up to 65 Years

  NCT07443592· PETHEMA Foundation· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Not yet recruiting

  SAVE trial

  2025-523709-13-00· Phase 3· Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau· Source

Showing 50 of 337.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer29 recruiting
• Colorectal cancer16 recruiting
• Prostate cancer14 recruiting
• Metastatic breast cancer11 recruiting
• Gastric and oesophageal cancer10 recruiting
• Bladder cancer8 recruiting
• Stroke7 recruiting
• Heart failure6 recruiting
• Multiple sclerosis6 recruiting
• Triple-negative breast cancer6 recruiting
• Acute myeloid leukaemia5 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Chronic spontaneous urticaria5 recruiting
• Atrial fibrillation4 recruiting
• Bronchiectasis4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Pancreatic cancer4 recruiting
• ALS (motor neurone disease)3 recruiting
• Coronary artery disease3 recruiting
• Deep vein thrombosis and pulmonary embolism3 recruiting
• Depression3 recruiting
• High blood pressure3 recruiting
• Immune thrombocytopenia (ITP)3 recruiting
• Kidney cancer3 recruiting
• Neuroendocrine tumours3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Schizophrenia3 recruiting
• Aortic stenosis2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Childhood cancers2 recruiting
• Cystic fibrosis2 recruiting
• Endometrial cancer2 recruiting
• Epilepsy2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Hidradenitis suppurativa2 recruiting
• HIV2 recruiting
• IgA nephropathy2 recruiting
• Liver cirrhosis2 recruiting
• Osteoarthritis2 recruiting
• Ovarian cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Alzheimer disease1 recruiting
• Asthma1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Down syndrome1 recruiting
• Endometriosis1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Lupus (SLE)1 recruiting
• Obesity1 recruiting
• Postpartum depression1 recruiting
• Primary biliary cholangitis1 recruiting
• Thyroid cancer1 recruiting
• Tuberculosis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

  2025-524038-24-00· Phase 3· Praxis Precision Medicines Inc.· Source

• Active, not recruiting

  An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT07424144· Phase 3· Sanofi· Source

• Active, not recruiting

  Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

  NCT06931405· Phase 2· Blueprint Medicines Corporation· Source

• Completed

  Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria.

  2024-518786-10-01· Phase 2· Evommune Inc.· Source

• Recruiting

  Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures

  2024-514499-42-00· Phase 3· Neuraxpharm Pharmaceuticals S.L.· Source

• Completed

  Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis

  NCT07105163· Procare Health Iberia S.L.· Source

• Completed

  An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures

  2024-517061-16-01· Phase 2· Praxis Precision Medicines Inc.· Source

• Completed

  A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

  2023-505908-28-00· Phase 1· Laboratorios Liomont S.A. de C.V.· Source

• Completed

  Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

  NCT05828303· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

  NCT06544733· Phase 2/3· Gilead Sciences Inc.· Source

• Completed

  A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

  2024-514559-13-00· Phase 2/3· Praxis Precision Medicines Inc.· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· AbbVie· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

  NCT06284954· Phase 2· argenx· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Alumis Inc· Source

• Completed

  Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

  2023-508819-23-00· Phase 1· Hutchmed Ltd.· Source

• Completed

  Impact of Perioperative Hyperoxia on Cancer Recurrence and Mortality After Elective Colorectal Cancer Surgery

  NCT06989346· Parc de Salut Mar· Source

• Completed

  A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

  NCT06195930· Phase 2· Bayer· Source

• Completed

  A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

  NCT05954143· Phase 2· Bolt Biotherapeutics Inc.· Source

• Completed

  Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease.

  2023-506432-32-00· Phase 4· Bellvitge University Hospital· Source

• Withdrawn

  The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  NCT06291415· Phase 1· Hutchmed· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

  NCT06168409· Phase 3· AstraZeneca· Source

• Completed

  This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Spontaneous Urticaria (CSU) to assess if it is effective and safe.

  2023-504799-94-00· Phase 2· Escient Pharmaceuticals Inc.· Source

• Completed

  VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

  NCT06214052· Phase 2· ViiV Healthcare· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06212999· Phase 3· Incyte Corporation· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Ryvu Therapeutics SA· Source

• Completed

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source

• Completed

  A randomized, multi-centre, double-blind, phase II clinical trial of dose finding of Montelukast in patients with erosive osteoarthritis of the hands. HOME study.

  2023-506137-30-00· Phase 2· Farmalider S.A.· Source

• Completed

  Metabolomics and Bariatric Surgery in Patients With Metabolically Unhealthy Obesity

  NCT06297928· Parc de Salut Mar· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

  NCT06017609· Phase 2· Shionogi Inc.· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· AstraZeneca· Source

• Completed

  GRemubamab ErAdication Trial (GREAT-2)

  2022-502494-41-00· Phase 2· NHS Tayside· Source

• Completed

  A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

  NCT05963984· Phase 2· Carrick Therapeutics Limited· Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Phase 2· Inspirna, Inc.· Source

• Completed

  Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. “TRANSCENDER Study”

  NCT05744375· Phase 2· Grupo Espanol De Investigacion En Cancer De Mama· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· MacroGenics· Source

• Terminated

  Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

  NCT06077773· Phase 2· Escient Pharmaceuticals, Inc· Source

• Completed

  BPL-003 Efficacy and Safety in Treatment Resistant Depression

  NCT05870540· Phase 2· Beckley Psytech Limited· Source

• Recruiting

  A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors

  NCT05642780· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.· Source

• Completed

  A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer

  2023-503356-27-00· Phase 2· Inspirna Inc.· Source

• Completed

  Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

  NCT05635734· Phase 1/2· Cantex Pharmaceuticals· Source

• Completed

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· Phase 2/3· Kartos Therapeutics Inc.· Source

• Completed

  TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

  NCT03529448· Phase 1/2· Grupo Español de Investigación en Neurooncología· Source

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Biogen· Source

• Completed

  Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

  NCT05834738· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)

  NCT05757570· Phase 1/2· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

Showing 50 of 186.

Conditions

Diseases this institution publishes on or runs trials for.

• Bronchiectasis10 works · 5 trials
• Hidradenitis suppurativa8 works · 9 trials
• Myeloproliferative neoplasms8 works · 9 trials
• Myelodysplastic syndromes7 works · 4 trials
• Chronic spontaneous urticaria6 works · 15 trials
• Immune thrombocytopenia (ITP)5 works · 10 trials
• Follicular lymphoma5 works · 6 trials
• Uterine fibroids4 works · 0 trials